Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
SABA dependence is a key indicator of asthma control. If a patient is using their SABA more than twice per week, it could indicate poor control.*1
Compared with BUD/Form, Relvar is associated with a 10% reduction in SABA use in real-world settings.2
This graph has been independently created by GSK from the original data. The same results were first published in Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.
Without Relvar, Oscar was frequently using his SABA reliever to address symptoms. But now that he’s using his reliever less frequently, Oscar’s experiencing far fewer interruptions to his daily life!
From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.
*Within the last four weeks. Other important criteria include: daytime symptoms more than twice/week; any night waking due to asthma; any activity limitation due to asthma.
BUD, budesonide; CI, confidence interval; Form, formoterol; SABA, short-acting β2-agonist.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210004